Our team
The Delix team is on a mission. We share a passion for using revolutionary science to help patients who have not been served well by traditional approaches. We tackle significant unmet medical needs by balancing innovation with rigor, speed with safety.
We are using our neuroplasticity platform to push the frontiers of neuroscience. By broadening access to the promise of psychoplastogens, we are opening new horizons in CNS drug discovery focused on circuit-based approaches to improve brain disorders.
Headquartered in Massachusetts, the Delix team is pioneering efforts to understand how reversing cortical atrophy and re-wiring pathological neural circuits can drive rapid and sustained healing for people suffering from many psychiatric and neurological diseases. We aren’t satisfied with treating brain disorders. We aim to cure them.
Delix Team
Mark Rus, MSc.
Chief Executive Officer
David Olson, PhD
Chief Innovation Officer, Head of SAB, Co-Founder
Eliseo Salinas
Head of Research & Development
Kurt Rasmussen, PhD
Chief Scientific Officer
Tricia McCall
Chief People Officer
Retsina Meyer, PhD
Head of Corporate Strategy
Matt Gorman
Chief Financial Officer
Milan Chytil, PhD
Director of Medicinal Chemistry
Sharon Engel, PhD
Senior Director of Pharmacology
Scientific & Strategic Advisory Board
David Olson, PhD
Head of the SAB and Chief Innovation Officer
Craig Lindsley, PhD
Editor-in-Chief, Journal of Medicinal Chemistry; Professor of Pharmacology, Chemistry and Biochemistry at Vanderbilt University; Director of the Warren Center for Neuroscience Drug Discovery
Florence Wagner, PhD
Associate Director of the Center for the Development of Therapeutics at the Broad Institute
Conor Liston, MD, PhD
Associate Professor of Neuroscience and Psychiatry at Weill Cornell Medicine
Jacob Hooker, PhD
Professor of Radiology, Harvard Medical School
Stephen Stahl, MD, PhD
Professor of Psychiatry, University of California, San Diego
Michael Cola
President and CEO of Avalo Therapeutics
John Krystal, M.D.
Professor at Yale University School of Medicine
Board of Directors
Vasudev Bailey, PhD
Senior Partner at ARTIS Ventures
Nick Haft
Managing Director at OMX Ventures
David Olson, PhD
Chief Innovation Officer, Head of SAB, Co-Founder
Mark Rus, MSc.
Chief Executive Officer